Alix Ventures backs pre‑seed and seed‑stage “TechBio” companies—startups engineering biology with computational and automation tools to accelerate therapeutics, diagnostics and biomanufacturing—believing these platforms will drive radical advances in human health.

What is the goal of the Residency?

The Residency equips aspiring TechBio investors and founders with structured training and live deal exposure inside a specialist seed fund.

How competitive is admission?

Roughly one percent of applicants are accepted each cycle, ensuring a high‑touch experience.

Do Residents need VC experience?

No. Technical curiosity, founder access and the capacity to learn quickly are valued over prior investing roles.

Is the program paid?

No. The Residency is unpaid and carries no tuition; value comes from experience, network and placement support.

How long is the commitment?

Six months minimum with an option to extend to 12 months for deeper portfolio engagement.

Can Residents invest personal capital?

Yes, but only after compliance review and founder consent; personal checks do not affect the core fund’s terms.

What happens after graduation?

Alumni join a private Slack, receive ongoing mentorship and are prioritized for open roles at Alix Ventures and portfolio companies.

Are international applicants eligible?

Yes—the program is fully remote; time‑zone overlap for live calls is helpful but not mandatory.

What sectors does the fund focus on?

Synthetic biology, biomanufacturing, computational biology, and enablement tools that speed discovery and scale.

Does Alix guarantee full‑time jobs?

No guarantee, but the placement rate into VC or TechBio startups exceeds 80 percent within six months of completion.

‍